Synapse - Even Rustad

Results (13)

Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma the MANHATTAN nonrandomized clinical trial

Journal Article

Landgren, O.; Hultcrantz, M.; Diamond, B.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Tan, C.; Shah, U. A.; Lu, S. X.; Salcedo, M.; more...
JAMA Oncology (2021)

Fulltext@MSK | Save

Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: A single-arm, single-centre, phase 2 trial

Journal Article

Diamond, B.; Korde, N.; Lesokhin, A. M.; Smith, E. L.; Shah, U.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Tan, C.; more...
The Lancet Haematology (2021)

Fulltext@MSK | Save

Initial whole-genome sequencing of plasma cell neoplasms in first responders and recovery workers exposed to the World Trade Center attack of September 11, 2001

Journal Article

Maura, F.; Diamond, B.; Maclachlan, K. H.; Derkach, A.; Yellapantula, V. D.; Rustad, E. H.; Hultcrantz, M.; Shah, U. A.; Hong, J.; Landau, H. J.; more...
Clinical Cancer Research (2021)

Fulltext@MSK | Save

Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy in newly diagnosed multiple myeloma: final results from a clinical and correlative phase 2 study

Meeting Abstract

Landgren, O.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Tan, C.; Shah, U. A.; Lu, S. X.; Diamond, B.; Salcedo, M.; more...
Blood (2020)

Fulltext@MSK | Save

Long-term sustained minimal residual disease (MRD) negativity in patients with multiple myeloma treated with continuous lenalidomide maintenance therapy: A clinical and correlative phase 2 study

Meeting Abstract

Diamond, B.; Korde, N.; Lesokhin, A. M.; Smith, E. L.; Shah, U. A.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Tan, C.; more...
Blood (2020)

Fulltext@MSK | Save

Initial whole genome sequencing of plasma cell neoplasms in first responders and recovery workers exposed to the World Trade Center attack of September 11, 2001

Meeting Abstract

Diamond, B.; Maclachlan, K. H.; Derkach, A.; Yellapantula, V.; Rustad, E. H.; Hultcrantz, M.; Shah, U. A.; Hong, J.; Landau, H. J.; Iacobuzio-Donahue, C.; more...
Blood (2020)

Fulltext@MSK | Save

Accelerated single cell seeding in relapsed multiple myeloma

Journal Article

Landau, H. J.; Yellapantula, V.; Diamond, B. T.; Rustad, E. H.; Maclachlan, K. H.; Gundem, G.; Medina-Martinez, J.; Arango Ossa, J.; Levine, M. F.; Zhou, Y.; more...
Nature Communications (2020)

Fulltext@MSK | Save

Long-term sustained minimal residual disease (MRD) negativity in multiple myeloma patients treated with lenalidomide maintenance therapy: A clinical and correlative phase 2 study

Meeting Abstract

Landgren, O.; Mastey, D.; Lesokhin, A. M.; Smith, E. L.; Shah, U. A.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Salcedo, M.; more...
Blood (2019)

Fulltext@MSK | Save

Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy provides unprecedented MRD negativity rates in newly diagnosed multiple myeloma: A clinical and correlative phase 2 study